Search results
Results from the WOW.Com Content Network
KarXT is expected to drive sales through late-2020s and into the next decade, at a time when two of Bristol Myers' top drugs, blood cancer treatment Revlimid and blood thinner Eliquis face generic ...
(Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older ...
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading on Friday. Bristol Myers obtained drug Cobenfy, also known as KarXT, through its $14 billion takeover of ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey , [ 2 ] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
It is developed by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb. [3] Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, [ 4 ] [ 5 ] and became available in February 2020. [ 2 ]
Royalty Pharma owns royalties on more than 35 commercial products, including Bristol Myers Squibb's recently approved schizophrenia drug KarXT and Johnson & Johnson's blockbuster treatments ...
The drugmaker said it would focus on licensing, partnerships and bolt-on purchases as opposed to large acquisitions after signing two multi-billion dollar deals last month. In December, Bristol ...